SummitTX Capital’s Eli Lilly LLY Stock Holding History

SummitTX Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,881	Closed	-$37.5M	–	885
2025 Q4	$37.5M	Buy	34,881 +32,481	+1,353%	+$31.1M	1.13%	6
2025 Q3	$1.83M	Sell	2,400 -19,169	-89%	-$14.3M	0.08%	273
2025 Q2	$16.8M	Buy	21,569 +14,768	+217%	+$11.5M	0.72%	17
2025 Q1	$5.62M	Buy	+6,801	New	+$5.66M	0.24%	102

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SummitTX Capital's LLY Position: Q1 2026 in Review

SummitTX Capital sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 34,881 shares — an estimated $37.5M sold.

SummitTX Capital first reported a position in LLY in Q1 2025 and held it in 4 quarters. The position peaked at $37.5M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

SummitTX Capital reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 34,881 Eli Lilly shares in Q1 2026, an estimated $37.5M.
SummitTX Capital first reported a position in Eli Lilly in Q1 2025 and held it in 4 quarters.
SummitTX Capital's Eli Lilly position peaked at $37.5M in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.